ABL1 and nasopharyngeal carcinoma: Although the use of α-TOH is beneficial, the effects of the c-Abl inhibitor Neurotinib exceed those of this nutraceutical in the inactivation of p-c-Abl and nuclear localization of TFEB in NPC models.